Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051736701> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2051736701 endingPage "166" @default.
- W2051736701 startingPage "163" @default.
- W2051736701 abstract "Recent evidence has shown that endocrine tumors are under an endocrine and an immune regulation, and that biotherapies with interferon or the long-acting somatostatin analog octreotide may be effective in the control of tumor growth and clinical symptomatology. Within the biotherapies of tumors, interleukin-2(IL-2) has appeared to play an essential role in the antitumor immune response. Despite its important antitumor role, very few studies have been carried out to investigate the possible use of IL-2 in the treatment of advanced endocrine tumors. Its potential toxicity would represent the main limiting factor for the clinical experiments with IL-2. Our previous studies have shown that the pineal hormone melatonin (MLT) may amplify the antitumor activity of IL-2, either through immunomodulating mechanisms or through a direct cytostatic activity by inhibiting tumor growth factor production. On this basis, we have performed a phase II pilot study with low-dose IL-2 plus MLT in 14 patients with untreatable endocrine tumors because of disseminated disease, lack of response to previous standard biotherapies or chemotherapies, or tumors for whom no effective therapy is available. Thyroid cancers, carcinoid and endodrine pancreatic tumors were the most frequent neoplasms. IL-2 was given at 3 million IU/day s.c. at 8 p.m. for 6 days/week for 4 weeks, corresponding to one cycle. MLT was given orally at 40 mg/day at 8 p.m. every day. In nonprogressed patients, a second cycle was given after a 21-day rest period. Patients were considered as evaluable when they received at least one complete cycle, and 12 patients were fully evaluable. According to WHO criteria, a partial response was achieved in 3/12 (25%) patients (carcinoid tumor: 1; neuroendocrine lung tumor: 1; pancreatic islet cell tumor: 1). Another patient with gastrinoma had a more than 50% reduction of tumor markers. Toxicity was low in all patients. This preliminary study suggests that low-dose IL-2 immunotherapy in association with the pineal hormone MLT may constitute a new well-tolerated and potentially active therapy of untreatable advanced endocrine tumors." @default.
- W2051736701 created "2016-06-24" @default.
- W2051736701 creator A5026158008 @default.
- W2051736701 creator A5030301955 @default.
- W2051736701 creator A5061179981 @default.
- W2051736701 creator A5073716808 @default.
- W2051736701 creator A5074145474 @default.
- W2051736701 creator A5086265337 @default.
- W2051736701 creator A5087341169 @default.
- W2051736701 date "1995-01-01" @default.
- W2051736701 modified "2023-10-17" @default.
- W2051736701 title "Immunoendocrine Therapy with Low-Dose Subcutaneous lnterleukin-2 plus Melatonin of Locally Advanced or Metastatic Endocrine Tumors" @default.
- W2051736701 doi "https://doi.org/10.1159/000227450" @default.
- W2051736701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7854778" @default.
- W2051736701 hasPublicationYear "1995" @default.
- W2051736701 type Work @default.
- W2051736701 sameAs 2051736701 @default.
- W2051736701 citedByCount "35" @default.
- W2051736701 countsByYear W20517367012012 @default.
- W2051736701 countsByYear W20517367012013 @default.
- W2051736701 countsByYear W20517367012014 @default.
- W2051736701 countsByYear W20517367012015 @default.
- W2051736701 countsByYear W20517367012016 @default.
- W2051736701 countsByYear W20517367012018 @default.
- W2051736701 countsByYear W20517367012019 @default.
- W2051736701 crossrefType "journal-article" @default.
- W2051736701 hasAuthorship W2051736701A5026158008 @default.
- W2051736701 hasAuthorship W2051736701A5030301955 @default.
- W2051736701 hasAuthorship W2051736701A5061179981 @default.
- W2051736701 hasAuthorship W2051736701A5073716808 @default.
- W2051736701 hasAuthorship W2051736701A5074145474 @default.
- W2051736701 hasAuthorship W2051736701A5086265337 @default.
- W2051736701 hasAuthorship W2051736701A5087341169 @default.
- W2051736701 hasConcept C126322002 @default.
- W2051736701 hasConcept C134018914 @default.
- W2051736701 hasConcept C143998085 @default.
- W2051736701 hasConcept C2776297358 @default.
- W2051736701 hasConcept C2778182776 @default.
- W2051736701 hasConcept C2779066768 @default.
- W2051736701 hasConcept C2781025020 @default.
- W2051736701 hasConcept C46699223 @default.
- W2051736701 hasConcept C71315377 @default.
- W2051736701 hasConcept C71924100 @default.
- W2051736701 hasConceptScore W2051736701C126322002 @default.
- W2051736701 hasConceptScore W2051736701C134018914 @default.
- W2051736701 hasConceptScore W2051736701C143998085 @default.
- W2051736701 hasConceptScore W2051736701C2776297358 @default.
- W2051736701 hasConceptScore W2051736701C2778182776 @default.
- W2051736701 hasConceptScore W2051736701C2779066768 @default.
- W2051736701 hasConceptScore W2051736701C2781025020 @default.
- W2051736701 hasConceptScore W2051736701C46699223 @default.
- W2051736701 hasConceptScore W2051736701C71315377 @default.
- W2051736701 hasConceptScore W2051736701C71924100 @default.
- W2051736701 hasIssue "2" @default.
- W2051736701 hasLocation W20517367011 @default.
- W2051736701 hasLocation W20517367012 @default.
- W2051736701 hasOpenAccess W2051736701 @default.
- W2051736701 hasPrimaryLocation W20517367011 @default.
- W2051736701 hasRelatedWork W158565870 @default.
- W2051736701 hasRelatedWork W1993421446 @default.
- W2051736701 hasRelatedWork W1994215581 @default.
- W2051736701 hasRelatedWork W2035624349 @default.
- W2051736701 hasRelatedWork W2047764997 @default.
- W2051736701 hasRelatedWork W2157939113 @default.
- W2051736701 hasRelatedWork W2733671530 @default.
- W2051736701 hasRelatedWork W2943651504 @default.
- W2051736701 hasRelatedWork W4256234604 @default.
- W2051736701 hasRelatedWork W777362865 @default.
- W2051736701 hasVolume "52" @default.
- W2051736701 isParatext "false" @default.
- W2051736701 isRetracted "false" @default.
- W2051736701 magId "2051736701" @default.
- W2051736701 workType "article" @default.